KRYS - クリスタル・バイオテック （Krystal Biotech Inc.）

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5 th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.

Jeune Aesthetics said that phase 1 data showed that KB301, a gene-based treatment designed to address the biology of aging skin to treat wrinkles, demonstrated durability over nine months.

Krystal Biotech Inc''s (NASDAQ: KRYS ) subsidiary Jeune Aesthetics Inc , announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301 to address the underlying biology of aging skin for improvement of fine lines and wrinkles. Ten subjects from the PEARL-1 efficacy cohort were enrolled in the PEARL-1 extension cohort, an open-label study to assess the duration of … Full story available on Benzinga.com

In this piece, we will take a look at the five most promising gene therapy companies to watch. For more companies, take a look at 10 Most Promising Gene Therapy Companies to Watch. 5. Krystal Biotech, Inc. (NASDAQ:KRYS) Market Capitalization as of November 12, 2022: $1.97 billion Krystal Biotech, Inc. (NASDAQ:KRYS) develops treatments for rare […]

Development delays across the pipeline risks losing interest on Wall Street, which has the attention span of a goldfish.

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS ) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17, 2023. The Biologics License Application (BLA) submission for B-VEC is supported by the clinical data readouts from the GEM-3 and … Full story available on Benzinga.com

Krystal Biotech (KRYS) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis…

Krystal Biotech press release (KRYS): Q2 GAAP EPS of -$1.10 misses by $0.07.Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments.

The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10- Q and with the audited financial statements and the related notes included in our Annual…

Krystal Biotech, Inc. Misses Q2 EPS by 9c

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS ) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17, 2023. The Biologics License Application (BLA) submission for B-VEC is supported by the clinical data readouts from the GEM-3 and … Full story available on Benzinga.com

Krystal Biotech (KRYS) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis…

Krystal Biotech press release (KRYS): Q2 GAAP EPS of -$1.10 misses by $0.07.Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments.

The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10- Q and with the audited financial statements and the related notes included in our Annual…

Krystal Biotech, Inc. Misses Q2 EPS by 9c